基于肠-脑轴探讨艾灸治疗卒中后认知功能障碍的临床疗效和机制研究

注册号:

Registration number:

ITMCTR2025001116

最近更新日期:

Date of Last Refreshed on:

2025-06-04

注册时间:

Date of Registration:

2025-06-04

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

基于肠-脑轴探讨艾灸治疗卒中后认知功能障碍的临床疗效和机制研究

Public title:

Clinical efficacy and mechanism research on the treatment of post-stroke cognitive dysfunction by moxibustion based on the gut-brain axis

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于肠-脑轴探讨艾灸治疗卒中后认知功能障碍的临床疗效和机制研究

Scientific title:

Clinical efficacy and mechanism research on the treatment of post-stroke cognitive dysfunction by moxibustion based on the gut-brain axis

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

于梦芸

研究负责人:

于梦芸

Applicant:

YU Mengyun

Study leader:

YU Mengyun

申请注册联系人电话:

Applicant telephone:

13718862203

研究负责人电话:

Study leader's telephone:

13718862203

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

myu1@bucm.edu.cn

研究负责人电子邮件:

Study leader's E-mail:

myu1@bucm.edu.cn

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

北京丰台方庄芳星园一区6号南楼针灸科

研究负责人通讯地址:

北京丰台方庄芳星园一区6号南楼针灸科

Applicant address:

Department of Acupuncture South Building No. 6 fangxingyuan Fengtai District Beijing

Study leader's address:

Department of Acupuncture, South Building, No. 6 fangxingyuan Fengtai District, Beijing

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

北京中医药大学东方医院

Applicant's institution:

Dongfang Hospital Beijing University of Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

JDF-IRB-2025031102

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

北京中医药大学东方医院临床研究伦理委员会

Name of the ethic committee:

IRB of Dongfang Hospital Beijing University of Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2025/2/27 0:00:00

伦理委员会联系人:

夏芸

Contact Name of the ethic committee:

Xia Yun

伦理委员会联系地址:

北京市丰台区方庄芳星园一区6号东方医院东楼南支444

Contact Address of the ethic committee:

South Branch 444, East Building, No. 6 fangxingyuan Fengtai District, Beijing

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 010 67654807

伦理委员会联系人邮箱:

Contact email of the ethic committee:

dfyyec@126.com

研究实施负责(组长)单位:

北京中医药大学东方医院

Primary sponsor:

Dongfang Hospital Beijing University of Chinese Medicine

研究实施负责(组长)单位地址:

北京丰台方庄芳星园一区6号南楼针灸科

Primary sponsor's address:

Department of Acupuncture South Building No. 6 fangxingyuan Fengtai District Beijing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

北京中医药大学东方医院

具体地址:

北京丰台方庄芳星园一区6号

Institution
hospital:

Dongfang Hospital Beijing University of Chinese Medicine

Address:

No. 6 fangxingyuan Fengtai District, Beijing

经费或物资来源:

北京中医药大学揭榜挂帅项目

Source(s) of funding:

Beijing University of Chinese Medicine "decoding Chinese medicine" reveal the main project

研究疾病:

脑卒中后认知障碍

研究疾病代码:

Target disease:

Post-stroke cognitive impairment

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

其它

Others

研究目的:

本课题拟观察艾灸神阙穴对PSCI患者疗效指标(认知功能、情绪状态、生活能力)、肠道内环境(菌群结构、丰度及多样性,短链脂肪酸浓度)、血清炎性指标(白介素6、肿瘤坏死因子α、C反应蛋白)的影响,探讨艾灸神阙穴是否通过肠—脑轴的良性调控,改善机体炎症反应,从而改善认知功能。

Objectives of Study:

This research project aims to observe the effects of moxibustion on Shenque acupoint on the therapeutic indicators of patients with PSCI (such as cognitive function, emotional state, and living ability), the intestinal internal environment (bacterial community structure, abundance and diversity, short-chain fatty acid concentration), and serum inflammatory indicators (interleukin 6, tumor necrosis factor α, C-reactive protein), and to explore whether moxibustion on Shenque acupoint can improve the inflammatory response of the body through the benign regulation of the gut-brain axis, thereby improving cognitive function.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

PSCI患者纳入标准: (1)符合上述PSCI诊断标准; (2)10分≤蒙特利尔认知评估量表(MoCA)评分<26分。 (3)年龄30~75 岁,无性别要求; (4)病程1个月~1年; (5)入组前未使用过改善认知功能的药物; (6)意识清醒,生命体征平稳; (7)自愿参与本研究,并签署知情同意书。 健康受试者纳入标准: (1)年龄为18-65岁,性别不限。 (2) 经过系统健康体检确认无明显疾病,身体状况良好,无既往重大疾病史(如心脑血 管、神经系统、免疫系统、消化系统等疾病)。 (3) 通过认知功能评估确认认知功能正常不存在认知障碍或精神疾病。 (4) 能够理解研究内容,自愿签署知情同意书。

Inclusion criteria

Inclusion criteria for PSCI patients: (1) Conform to the above-mentioned PSCI diagnostic criteria; (2) 10 ≤ MoCA score of Montreal Cognitive Assessment Scale < 26; (3) Age range of 30 to 75 years old no gender requirement; (4) Duration of disease ranging from 1 month to 1 year; (5) No use of drugs for improving cognitive function before enrollment; (6) Consciousness clear stable vital signs; (7) Voluntary participation in this study and signing the informed consent form. Inclusion criteria for healthy subjects: (1) Age between 18 and 65 years old with no gender restrictions.(2) Confirmed to have no significant diseases through a systematic health examination in good physical condition and without a history of major diseases (such as cardiovascular and cerebrovascular diseases neurological disorders immune system disorders digestive system diseases etc.).(3) Confirmed to have normal cognitive function through cognitive function assessment with no cognitive impairment or mental disorders.(4) Able to understand the research content and voluntarily sign the informed consent form.

排除标准:

PSCI患者排除标准: (1)存在可导致认知功能障碍的其他疾病,如颅内占位病变、脑外伤、动脉血管瘤等; (2)伴有严重影响认知功能检查的疾病如视听功能异常、精神异常,无法配合诊疗; (3)本次发病前已存在明显认知能力减退或痴呆病史; (4)伴有其他严重疾病如免疫疾病、内分泌疾病、肝肾功能异常或有严重出血倾向; (5)妊娠或哺乳期妇女; (6)艾灸过敏以及不耐受者; (7)正在参加其他临床试验。 健康受试者排除标准: (1)近 3 个月内使用过抗生素、益生菌、免疫调节剂或其他可能影响肠道菌群组成的药 物或保健品。 (2)有胃肠道手术史或慢性胃肠疾病(如炎症性肠病、肠易激综合征等)。 (3)存在急性或慢性炎症性疾病、感染性疾病或其他可能干扰肠道菌群稳定性的情况。 (4)孕妇、哺乳期妇女及其他可能因生理状态而影响菌群数据的特殊人群。 (5)长期酗酒、吸烟或存在其他可能显著影响肠道菌群构成的生活方式问题。

Exclusion criteria:

Exclusion criteria for PSCI patients: (1) There are other diseases that can lead to cognitive impairment such as intracranial space-occupying lesions brain trauma and arteriovenous malformations etc.(2) There are diseases that seriously affect cognitive function tests such as abnormal auditory and visual functions mental disorders and inability to cooperate with diagnosis and treatment.(3) There was obvious cognitive decline or dementia history before this onset.(4) There are other serious diseases such as immune diseases endocrine diseases abnormal liver and kidney functions or severe bleeding tendencies.(5) Pregnant or lactating women.(6) Those who are allergic or intolerant to moxibustion.(7) Those who are participating in other clinical trials. Exclusion criteria for healthy subjects: (1) Have used antibiotics probiotics immunomodulators or other drugs or health supplements that may affect the composition of the intestinal flora within the last three months.(2) Have a history of gastrointestinal surgery or chronic gastrointestinal diseases (such as inflammatory bowel disease irritable bowel syndrome etc.).(3) Have acute or chronic inflammatory diseases infectious diseases or other conditions that may interfere with the stability of the intestinal flora.(4) Pregnant women lactating women and other special groups whose physiological conditions may affect the flora data.(5) Have a long-term habit of heavy drinking smoking or other lifestyle issues that may significantly affect the composition of the intestinal flora.

研究实施时间:

Study execute time:

From 2025-06-30

To      2028-02-25

征募观察对象时间:

Recruiting time:

From 2025-06-30

To      2028-02-25

干预措施:

Interventions:

组别:

艾灸组

样本量:

42

Group:

Moxibustion group

Sample size:

干预措施:

艾灸神阙+常规内科基础治疗及康复治疗

干预措施代码:

Intervention:

Acupuncture at RN8 + conventional internal medicine basic treatment and rehabilitation therapy

Intervention code:

组别:

健康对照者

样本量:

10

Group:

Healthy control group

Sample size:

干预措施:

不进行任何治疗

干预措施代码:

Intervention:

nothing

Intervention code:

组别:

艾灸对照组

样本量:

42

Group:

Moxibustion control group

Sample size:

干预措施:

智能电子艾灸设备置于神阙加热+常规内科基础治疗及康复治疗

干预措施代码:

Intervention:

Place the intelligent electronic moxibustion device at Shenshu point for heating+conventional internal medicine basic treatment and rehabilitation therapy

Intervention code:

样本总量 Total sample size : 94

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

北京中医药大学东方医院

单位级别:

三级甲等医院

Institution/hospital:

Dongfang Hospital Beijing University of Chinese Medicine

Level of the institution:

Tertiary A Hospital

测量指标:

Outcomes:

指标中文名:

气相色谱法(GC-MS)检测粪便中SCFAs浓度

指标类型:

次要指标

Outcome:

Determination of Short-Chain Fatty Acids in Feces by Gas Chromatography – Mass Spectrometry (GC-MS)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血液指标检测

指标类型:

次要指标

Outcome:

Blood index testing

Type:

Secondary indicator

测量时间点:

测量方法:

酶联免疫吸附试验

Measure time point of outcome:

Measure method:

ELISA

指标中文名:

汉密尔顿焦虑量表

指标类型:

次要指标

Outcome:

Hamilton Anxiety Scale,HAMA

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

简易易智力状态检查量表

指标类型:

次要指标

Outcome:

Mini-mental State Examination,MMSE

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

蒙特利尔认知评估量表

指标类型:

主要指标

Outcome:

Montreal Cognitive Assessment,MoCA

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

16S rRNA 法检测受试者肠道菌群

指标类型:

次要指标

Outcome:

Microbial Population Analysis Based on 16S rRNA Detection

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

改良型巴塞尔指数

指标类型:

次要指标

Outcome:

Modified Barthel Index,MBI

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

匹兹堡睡眠质量指数量表

指标类型:

次要指标

Outcome:

Pittsburgh Sleep Quality Index,PSQI

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

汉密尔顿抑郁量表

指标类型:

次要指标

Outcome:

Hamilton Depression Scale,HAMD

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

粪便

组织:

Sample Name:

feces

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

标本中文名:

血液

组织:

静脉

Sample Name:

Blood

Tissue:

vein

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 18
Min age years
最大 75
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

采用分层区组随机法将纳入的84例PSCI患者分为两组,每组42 例。采用 SPSS24.0 软件生成随机数字表,随机号码由不参与研究的其他人员保管,通过密闭不透明的信封方法实现分配隐藏。纳入 10 名健康受试者,健康受试者不参与分层区组随机,仅需在研究期间进行一次粪便样本采集。

Randomization Procedure (please state who generates the random number sequence and by what method):

The included 84 PSCI patients were divided into two groups using a stratified block randomization method, with 42 cases in each group. A random number table was generated using SPSS 24.0 software, and the random numbers were kept by personnel not involved in the study. Allocation concealment was achieved through sealed, opaque envelopes. Ten healthy subjects were included; these healthy subjects did not participate in the stratified block randomization and were only required to provide a single fecal sample during the study period.

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

no

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病历记录表保存于北京中医药大学东方医院

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The Case Record Forms will be kept at Dongfang Hospital Beijing University of Chinese Medicine

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统